Literature DB >> 27499261

Regulation of DEK expression by AP-2α and methylation level of DEK promoter in hepatocellular carcinoma.

Ming-Xu Qiao1, Chun Li1, Ai-Qun Zhang2, Ling-Ling Hou1, Juan Yang1, Hong-Gang Hu1.   

Abstract

DEK is overexpressed in multiple invasive tumors. However, the transcriptional regulatory mechanism of DEK remains unclear. In the present study, progressive-type truncation assay indicated that CpG2-2 (-167 bp/+35 bp) was the DEK core promoter, whose methylation inhibited DEK expression. Bisulfite genomic sequencing analysis indicated that the methylation levels of the DEK promoter in normal hepatic cells and tissues were higher than those in hepatocellular carcinoma (HCC) cells. TFSEARCH result revealed transcription factor binding sites in CpG2-2. Among the sites, the AP-2α binding site showed the most significant methylation difference; hence, AP-2α is a key transcription factor that regulates DEK expression. Point or deletion mutation of the AP-2α binding site significantly reduced the promoter activity. Chromatin immunoprecipitation assay demonstrated the binding of AP-2α to the core promoter. Furthermore, knock down of endogenous AP-2α downregulated DEK expression, whereas overexpression of AP-2α upregulated DEK expression. Thus, AP-2α is an important transcription factor of DEK expression, which is correlated with the methylation level of the DEK core promoter in HCC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27499261     DOI: 10.3892/or.2016.4984

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Long Non-Coding LEF1-AS1 Sponge miR-5100 Regulates Apoptosis and Autophagy in Gastric Cancer Cells via the miR-5100/DEK/AMPK-mTOR Axis.

Authors:  Huimin Zhang; Jun Wang; Yundan Wang; Jiapeng Li; Lili Zhao; Tongcun Zhang; Xinghua Liao
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

2.  MPO Promoter Polymorphism rs2333227 Enhances Malignant Phenotypes of Colorectal Cancer by Altering the Binding Affinity of AP-2α.

Authors:  Qingtao Meng; Shenshen Wu; Yajie Wang; Jin Xu; Hao Sun; Runze Lu; Na Gao; Hongbao Yang; Xiaobo Li; Boping Tang; Michael Aschner; Rui Chen
Journal:  Cancer Res       Date:  2018-03-14       Impact factor: 12.701

3.  LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy.

Authors:  Hong Yi; Rui Peng; Lu-Yu Zhang; Yan Sun; Hui-Min Peng; Han-Deng Liu; Li-Juan Yu; Ai-Ling Li; Ya-Juan Zhang; Wen-Hao Jiang; Zheng Zhang
Journal:  Cell Death Dis       Date:  2017-02-02       Impact factor: 8.469

4.  miR-25-3p, Positively Regulated by Transcription Factor AP-2α, Regulates the Metabolism of C2C12 Cells by Targeting Akt1.

Authors:  Feng Zhang; Kun Chen; Hu Tao; Tingting Kang; Qi Xiong; Qianhui Zeng; Yang Liu; Siwen Jiang; Mingxin Chen
Journal:  Int J Mol Sci       Date:  2018-03-08       Impact factor: 5.923

5.  DEK is highly expressed in breast cancer and is associated with malignant phenotype and progression.

Authors:  Mai-Qing Yang; Lin-Lin Bai; Zhao Wang; Lei Lei; Yi-Wen Zheng; Zhi-Han Li; Wen-Jing Huang; Chen-Chen Liu; Hong-Tao Xu
Journal:  Oncol Lett       Date:  2021-04-01       Impact factor: 2.967

Review 6.  The Art of War: harnessing the epigenome against cancer.

Authors:  Jonathan Nye; Daniël P Melters; Yamini Dalal
Journal:  F1000Res       Date:  2018-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.